DLL3 targeting Radio-DARPin MP0712 to enter first-in-human study in 2025, pending regulatory clearanceStrategic partnership with Orano Med on ...

On September 12, 2024, Orano Med signed a licensing agreement with Sanofi on the marketing rights for AlphaMedix, with Orano Med remaining responsible for its production thanks to its global ...

DLL3 targeting Radio-DARPin MP0712 to enter first-in-human study in 2025, pending regulatory clearance Strategic partnership with Orano Med on Radio-DARPins now expanded to ten programs MP0533 ...

Q4 2024 Earnings Call Transcript March 7, 2025 Operator: Good morning, and welcome to the Molecular Partners Fourth Quarter ...

Sanofi has firmed up its position in the red-hot area of radiopharmaceuticals for cancer with the purchase of a €300 million ($325 million) stake in Orano Med, a subsidiary of French nuclear ...

"Our strategic Radio-DARPin partnership with Orano Med, expanded in January, is progressing well, and we named MSLN as our second RDT program for development. We anticipate submitting an IND ...

And maybe most importantly, the third bullet point is the expansion of our Orano Med collaboration. And as you know, in the radio field, we bring the vector, but we still need access to an isotope.

Molecular Partners and Orano Med have expanded their co-development agreement to create four Radio-DARPin programs, with each company securing commercialization rights to two. The strengthened ...